tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Pharming Group Reports Strong Q2 2025 Financial Results and Business Update

Story Highlights
Pharming Group Reports Strong Q2 2025 Financial Results and Business Update

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Pharming Group ( (PHAR) ) has issued an update.

On July 31, 2025, Pharming Group reported a 26% increase in total revenues for the second quarter of 2025, driven by significant growth in RUCONEST® and Joenja® sales. The company achieved a positive operating profit of $10.8 million, reversing a loss from the previous year. Pharming raised its full-year revenue guidance and highlighted a study suggesting a potential 100-fold increase in APDS prevalence, which could expand Joenja®’s market. The company also launched Joenja® in the U.K. and submitted a regulatory filing in Japan, while advancing clinical trials for other pipeline products. Pharming is addressing U.S. tariffs but does not expect a material impact on its business.

The most recent analyst rating on (PHAR) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.

Spark’s Take on PHAR Stock

According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.

Pharming Group’s overall score is driven by a positive earnings call highlighting revenue growth and strategic initiatives. However, financial performance remains a concern with ongoing profitability issues and valuation challenges. Technical indicators suggest neutral momentum, contributing to a moderate overall score.

To see Spark’s full report on PHAR stock, click here.

More about Pharming Group

Pharming Group N.V. is a biotechnology company based in the Netherlands, focusing on the development and commercialization of innovative protein replacement therapies and precision medicines. Its primary products include RUCONEST®, used for the treatment of acute hereditary angioedema (HAE) attacks, and Joenja® (leniolisib), used for the treatment of activated PI3K delta syndrome (APDS). The company is committed to addressing significant, underserved markets and expanding its pipeline of therapies.

Average Trading Volume: 4,051

Technical Sentiment Signal: Buy

Current Market Cap: $664M

For detailed information about PHAR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1